Regeneron Pharmaceuticals and the company’s partner Sanofi voluntarily withdrew their application with the U.S. drug regulator for the expanded use of the anti-cancer drug Libtayo in patients with advanced cervical cancer.
If you are not happy with the results below please do another search
50 search results for:
Merck & Co. Inc. and partner Ridgeback Biotherapeutics said on Jan. 28 six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading Omicron variant.
A $2.1 million grant from the National Institutes of Health will allow University of Arizona Health Sciences researchers to study the links between knee structure changes and clinical outcomes in people with osteoarthritis.
This whitepaper covers the role that the BMC Helix portfolio can play in helping healthcare organizations to modernize their infrastructure and drive digital transformation.
Kate Rawson, one of the most insightful and practical observers of the health policy scene in Washington, offers the Coalition for Healthcare Communication her well-informed analysis and a Q&A format.
On the strength of data from Alzamend Neuro’s Phase I study of its lead compound AL001 being developed for the treatment of Alzheimer’s disease, the company is looking to commence a Phase II multiple ascending dose study for that indication during the second quarter of 2022.
The World Health Organization (WHO) is looking into allegations a regional director in Asia bullied staff, used racist language and leaked sensitive vaccine data to Japan, accusations the official denies.
The world’s first medical trial authorized to deliberately expose participants to the coronavirus is seeking more volunteers as it steps up efforts to help develop better vaccines.
While the Centers for Medicare & Medicaid Services undergoes the comment period on its national coverage decision for Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab), Biogen and its partner company Eisai released additional details about the Phase IV post-marketing study of the drug.
Ogilvy Health’s new chief creative officer Adam Hessel talks about why he crossed over into healthcare from the consumer sector, what he brings to Ogilvy Health, and where he wants to see the healthcare industry go in general when it comes to creativity.